Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery

被引:14
作者
Craven, Sharon
Dewar, Lori
Yang, Xianjun
Ginsberg, Jeff
Ofosu, Frederick
机构
[1] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada
[3] Canadian Blood Serv, Hamilton, ON, Canada
关键词
C-reactive protein; activated factor VII; activated factor X-tissue factor pathway inhibitor; prothrombin fragment 1+2;
D O I
10.1097/01.mbc.0000264704.90039.5d
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Up to 20% of patients develop venographically proven deep-vein thrombosis after elective orthopedic surgery even under the cover of heparin or low molecular weight heparin. The extent to which the chronic inflammation of osteoarthritis requiring elective orthopedic surgery alters in-vivo coagulation and whether any specific alteration influences the development of postoperative thrombosis are unknown. This study compared the concentrations of activated factor VII (FVIIa), tissue factor pathway inhibitor (TFPI), activated factor X (FXa)-TFPI, thrombin-antithrombin, and prothrombin fragment 1+2 (F1+2) in plasmas of 535 healthy individuals (ages 17-76) with those in the preoperative plasmas of 306 arthritis patients (ages 30-92) scheduled for elective knee or hip replacement surgery. C-reactive protein was also measured in the plasmas of approximately 15% of the participants. Age-adjusted concentrations of FVIIa, F1+2, and C-reactive protein were higher in patients than controls, while the concentrations of thrombin-antithrombin, TFPI and FXa-TFPI were similar. Chronic inflammation in the patients was thus associated with increased coagulation in vivo. Without compensatory increases in the concentrations of TFPI (natural inhibitor of prothrombinase), the elevated concentrations of FVIIa in the preoperative plasmas and the trauma associated with surgery may enhance the risk for developing postoperative deep-vein thrombosis.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 32 条
  • [1] ANDREW M, 1994, THROMB HAEMOSTASIS, V72, P836
  • [2] ARIENS RAS, 1995, BLOOD COAGUL FIBRIN, V6, P433
  • [3] Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor
    Baugh, RJ
    Broze, GJ
    Krishnaswamy, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (08) : 4378 - 4386
  • [4] Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
    Bergqvist, D
    Benoni, G
    Bjorgell, O
    Fredin, H
    Hedlundh, U
    Nicolas, S
    Nilsson, P
    Nylander, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) : 696 - 700
  • [5] Activation of inflammation and coagulation after infusion of C-reactive protein in humans
    Bisoendial, RJ
    Kastelein, JJP
    Levels, JHM
    Zwaginga, JJ
    van den Bogaard, B
    Reitsma, PH
    Meijers, JCM
    Hartman, D
    Levi, M
    Stroes, ESG
    [J]. CIRCULATION RESEARCH, 2005, 96 (07) : 714 - 716
  • [6] Cheras PA, 1997, CLIN ORTHOP RELAT R, P57
  • [7] Cofrancesco E, 1997, THROMB HAEMOSTASIS, V77, P267
  • [8] Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis
    Dahm, A
    Vlieg, AV
    Bendz, B
    Rosendaal, F
    Bertina, RM
    Sandset, PM
    [J]. BLOOD, 2003, 101 (11) : 4387 - 4392
  • [9] Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
    de Jonge, E
    Dekkers, PEP
    Creasey, AA
    Hack, CE
    Paulson, SK
    Karim, A
    Kesecioglu, J
    Levi, M
    van Deventer, SJH
    van der Poll, T
    [J]. BLOOD, 2000, 95 (04) : 1124 - 1129
  • [10] Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement -: A meta-analysis of prospective studies investigating symptomatic outcomes
    Douketis, JD
    Eikelboom, JW
    Quinlan, DJ
    Willan, AR
    Crowther, MA
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (13) : 1465 - 1471